Orthocell Ltd (AU:OCC) has released an update.
Orthocell Ltd has reported a striking 85% success rate in a clinical study of its Remplir nerve repair product, published in the Journal of Reconstructive Microsurgery Open. The study reveals that Remplir significantly aids in the recovery of muscle function in paralyzed upper limbs, marking a substantial advancement in peripheral nerve repair. With a potential US market worth over $1.1 billion, Orthocell’s breakthrough could position the company as a leader in the medical device sector for nerve repair solutions.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.
